Since the first attempt of pig-to-primate liver xenotransplantation (LXT) in 1968, survival has been limited. We evaluated a model utilizing a-1,3-galactosyltransferase knockout donors, continuous posttransplant infusion of human prothrombin concentrate complex, and immunosuppression including anti-thymocyte globulin, FK-506, methylprednisone, and costimulation blockade (belatacept, n = 3 or anti-CD40 mAb, n = 1) to extend survival. Baboon 1 remained well until postoperative day (POD) 25, when euthanasia was required because of cholestasis and plantar ulcers. Baboon 2 was euthanized following a seizure on POD 5, despite normal liver function tests (LFTs) and no apparent pathology. Baboon 3 demonstrated initial stable liver function but was euthanized on POD 8 because of worsening LFTs. Pathology revealed C4d positivity, extensive hemorrhagic necrosis, and a focal cytomegalovirus inclusion. Baboon 4 was clinically well with stable LFTs until POD29, when euthanasia was again necessitated by plantar ulcerations and rising LFTs. Final pathology was C4d negative and without evidence of rejection, inflammation, or thrombotic microangiopathy. Thus, nearly 1-mo rejection-free survival has been achieved following LXT in two of four consecutive recipients, demonstrating that the porcine liver can support life in primates for several weeks and has encouraging potential for clinical application as a bridge to allotransplantation for patients with acuteon-chronic or fulminant hepatic failure.
Introduction
Despite considerable advances in medical management and nonoperative strategies for treating end-stage liver disease, orthotopic liver transplantation (OLT) remains the primary therapeutic option. The clinical success of OLT has resulted in a disparity between supply and demand, with a resultant heightened focus on increasing the overall supply of organs available for transplantation. The use of porcine livers for clinical xenotransplantation could eliminate the shortage, and keen interest in this approach has been stimulated by recent advances in genome-editing technologies that promise to allow efficient generation of genetic modifications of donor swine to increase the likelihood of success (1) .
The first attempts at pig-to-primate liver xenotransplantation (LXT) date back to Sir Roy Calne's initial report in 1968, at which time immunosuppression was limited (consisting of a combination of azathioprine, hydrocortisone, and prednisolone), and maximum survival was 3.5 days (2) . Since this original report, multiple approaches utilizing different immunosuppression regimens have been attempted in search for a protocol that is well tolerated by the recipient and that provides prolonged survival. Interspecies incompatibilities, however, continued to lead to recipient demise characterized by the rapid onset of a lethal coagulopathy, severe thrombocytopenia, bleeding, and thrombotic microangiopathy (TMA) (3).
Our laboratory recently published encouraging results using a novel protocol in which exogenous coagulation factor administration appeared to circumvent this state of dysregulated coagulation following LXT. Baboon recipients of galactose-a-1,3-galactose knockout (GalT-KO) miniature swine livers showed spontaneous resolution of initial thrombocytopenia, markedly decreased transfusion requirements, and avoidance of TMA (4) . Although survival was initially limited to 7 days with this protocol, the addition of costimulation blockade to the protocol appeared to improve LXT survival from 9 to 25 days in a single recipient (5) . In this paper, we present our experience using this protocol in a series of four pig-to-baboon LXT experiments.
Methods

Pig-to-primate liver xenotransplantation
Recipient baboons (Papio hamadryus, n = 4) were purchased from the Mannheimer Foundation (Homestead, FL), and GalT-KO miniature swine donors were derived through breeding of previously cloned founders (6) , with demographics as shown in Table 1 . Four consecutive pig-to-baboon LXTs were carried out in a standard bicaval orthotopic fashion with posttransplant administration of a continuous human prothrombin concentrate complex (hPCC; Octaplex) infusion, as described previously (4, 5) . Splenectomy was performed at the time of LXT in all cases. Clinical monitoring was performed following the protocol previously reported by our laboratory (4, 5) . After LXT, all animals were cared for adhering to the principles of laboratory animal care, as described by the National Society for Medical Research, and the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 86-23, revised 1985). All experimental protocols were approved and in accordance with the Massachusetts General Hospital institutional animal care and use committee (2014N000276, 2009N000004). Baboon unique identifiers were simplified for the purpose of presentation in the text but were as follows: baboon 1 is B409, baboon 2 is B410, baboon 3 is B2216, and baboon 4 is B2616.
Immunosuppression
Induction immunosuppression for all recipients consisted of a single dose of anti-thymocyte globulin (ATG; 10 mg/kg; Genzyme, Cambridge, MA) on day À2 and cobra venom factor (100 lg/kg; Complement Technology, Tyler, TX) for complement factor (CH50) depletion on day À1. Maintenance immunosuppression consisted of a continuous tacrolimus (FK-506) infusion (0.20 mg/kg per day, with target serum levels of 10-20 ng/mL) starting on day À2 and a methylprednisone taper starting on day 0. Additional maintenance immunosuppression was provided with belatacept for costimulation blockade (n = 3; 20 mg/kg on days -1, 0, 4, 7, 14, and 21; Bristol-Myers Squibb, New York, NY) or anti-CD40 mAb (n = 1; 20 mg/kg on days 0, 5 and 10 mg/kg on day 7, and weekly thereafter; NHP Reagent Resource, Boston, MA).
Posttransplant in vitro analysis
Posttransplant assessment for circulating baboon antipig antibody levels and peripheral chimerism was performed. The latter was performed to evaluate evidence of graft-versus-host disease. Analyses were conducted by mixing 1 9 10 6 peripheral blood mononuclear cells (PBMCs) 
Histological examination and endothelial assessment
Routine liver biopsies to assess for rejection, inflammation, necrosis, and the presence of TMA were obtained per protocol, as described previously (4) . Immunohistochemistry staining for antibody-mediated rejection (C4d) and for baboon endothelial expression (CD31) targeting platelet/endothelial cell adhesion molecules (PECAM-1; DAKO/Agilent Technologies, Santa Clara, CA) was performed on formalin-fixed, paraffin-embedded tissue sections. Images were captured and viewed at varying magnification using a Nikon confocal microscope (Nikon DEclipse C1; Nikon, Tokyo, Japan) and reviewed by two transplant pathologists.
Polymerase chain reaction for porcine cytomegalovirus
DNA from PBMCs, spleen, and liver were obtained and analyzed in triplicate. Primers and probes specific for the porcine cytomegalovirus (pCMV) DNA polymerase gene were used per protocol, as described previously (7). Target DNA sequences were quantified by real-time polymerase chain reaction (PCR) using a Stratagene Mx3005P system (Agilent Technologies, Santa Clara, CA). Copies of cytomegalovirus (CMV) polymerase genes were assigned using standards made from amplicon cloned into TOPO pCR2.1, per the manufacturer's protocol (Life Technologies, ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CVF, cobra venom factor; CS, corticosteroids; POD, postoperative day.
Carlsbad, CA). The results were expressed as copy number of pCMVs per 300 ng of total tissue DNA.
Results
Belatacept
Baboon 1: The postoperative clinical course for this recipient of a pCMV-negative donor liver xenograft was described previously (4, 5) . In brief, spontaneous platelet count recovery began on popstoperative day (POD) 11, achieving a peak platelet count of 614 000 on POD 21 ( Figure 1 ). Figure 2 ). Euthanasia was required on POD 25 because of bleeding bilateral lower extremity pressure ulcers in the setting of postoperative lower extremity edema, as well as progressive cholestasis caused by a biliary stricture. Histology at the time of euthanasia demonstrated preserved hepatic architecture, mild inflammation, and no evidence of rejection or TMA. Immunohistochemistry analysis failed to detect the presence of C4d; however, the recipient demonstrated baboon CD31 expression within the porcine xenoliver along the sinusoidal endothelium at the peripheral and capsular areas, whereas the arteries, veins, and periportal venules were negative. Of note, given the potential tegumentary manifestations of graft-versus-host disease, baboon blood as well as lymph nodes were evaluated for peripheral donor chimerism on POD 25 and were found to be negative on flow cytometry analysis.
Baboon 2:
Following an uncomplicated intraoperative course utilizing a pCMV-negative donor liver xenograft, Baboon 2 recovered well and was alert and active shortly thereafter. Spontaneous platelet count recovery began on POD 4, reaching a peak count of 109 000 ( Figure 1 ). Minimal postoperative blood transfusion was required (150 mL total). The animal was noted to have a rising bilirubin level, with a peak of 14.5 mg/dL on the morning of POD 4. The latter was found to be caused by an anastomotic stricture that necessitated revision of the choledochocholedochostomy on POD 4. On the day following revision, bilirubin had decreased to 5.5 mg/dL, but the animal had a seizure of unclear etiology with subsequent respiratory demise and was euthanized.
Histology at the time of euthanasia demonstrated a normal xenograft without evidence of TMA, necrosis, or inflammation. The xenograft was C4d and CD31 negative, and postoperative in vitro analysis failed to detect the presence of any circulating cytotoxic baboon antipig antibodies following LXT.
Baboon 3:
Following an uncomplicated intraoperative course, baboon 3 recovered quickly and was active and eating shortly thereafter. Of note, the donor for baboon 3 was pCMV positive, as detected by PCR analysis (4509 AE 218 copies per 300 ng of DNA in PBMCs and 1,075 AE 364 copies per 300 ng of DNA in the spleen). The recipient did well through the first 6 days of the postoperative course, with platelet counts beginning to spontaneously rise on POD 5, reaching a peak platelet count of 56 000 (Figure 1 ). Blood transfusion requirement was again minimal. However, by POD 7, the LFTs began to rise and the hematocrit began to decrease. Worsening acidosis and liver function necessitated euthanasia on POD 8. Posttransplant pCMV PCR analysis revealed the liver xenograft to be pCMV positive (135 133 AE 8565 copies per 300 ng of DNA). In addition, peripheral blood assessment was positive for circulating cytotoxic IgM (but not IgG) at the time of euthanasia on POD 8. Histology at the time of euthanasia demonstrated marked hemorrhagic necrosis within the xenograft ( Figure 3A ) and a focal CMV inclusion. Immunohistochemistry staining was positive for C4d ( Figure 3B ) and negative for CD31.
Anti-CD40 mAb Baboon 4: Baboon 4 had an uncomplicated intraoperative course utilizing a pCMV-negative donor liver xenograft and was alert and active shortly thereafter. The animal had an uneventful postoperative course with relatively normal LFTs throughout most of the posttransplant period ( Figure 4A ). As with the previous long-term survivor, baboon 1, the platelet count of baboon 4 began to rise spontaneously by POD 7, reaching a peak platelet count of 709 000 by POD 20, with subsequent return to normal levels thereafter ( Figure 4B ). In addition, total blood transfusion requirements were minimal, totaling 300 mL over 29 days ( Figure 4B ). Unfortunately, in the setting of postoperative lower extremity edema, the animal developed worsening bleeding of bilateral plantar ulcerations and required euthanasia on POD 29. Necropsy revealed evidence of asymptomatic acute thrombosis of the main portal vein, likely correlating with the rise in LFTs and drop in fibrinogen that began on POD 27. However, the remainder of the xenograft appeared healthy ( Figure 4C ). Final histology did not demonstrate any pathology other than the presence of thrombus in the portal vein ( Figure 4D ). Immunohistochemical staining was negative for both C4d and CD31. Postoperative analysis did not detect the presence of any circulating cytotoxic antibodies or identify any peripheral donor chimerism of peripheral blood and lymph nodes on flow cytometry analysis. As expected, given the continuous administration of hPCC, circulating vitamin K-dependent factors were detected throughout the postoperative period ( Figure 5A ). In addition, postoperative assessment of non-vitamin K-dependent coagulation factor activity and fibrinogen demonstrated de novo coagulation factor production, indicating adequate xenograft function ( Figure 5B and 5C ).
Discussion
Since first described by Starzl et al in 1963 (8) , liver transplantation has emerged as the optimal therapy for patients with end-stage hepatic disease but has been limited by the shortage of organs available for transplantation. The organ-shortage crisis is further exacerbated by the absence of an effective means of temporary liver support that would ideally not only replace hepatic function until transplant but also treat the accompanying multiorgan failure, including hepatic encephalopathy, renal failure, and immune dysfunction (9) . These observations emphasize the critical need for immediate liver transplantation in the acutely ill, waitlisted population.
Clinical application of LXT remains an attractive goal and, with our current success, could serve as a bridge to allotransplantation for patients with acute-on-chronic or fulminant liver failure (10) . Further advancements in achieving long-term survival will be required prior to consideration of LXT as a destination therapy (10) . Pigs are thought to be the current best option for clinical xenotransplantation, given their anatomic and physiologic similarities to humans (11-13), favorable breeding characteristics (14) , and ability to undergo genetic modifications, which promise to overcome immunologic hurdles arising from their phylogenetic distance to humans. Until recently (5), however, survival was limited to ≤9 days, predominantly due to the development of a lethal coagulopathy, characterized by thrombocytopenia, bleeding, and TMA. Specifically, our laboratory developed a novel experimental approach to pig-to-primate LXT utilizing exogenous human coagulation factors and pCMV-free GalT-KO donors along with costimulation blockade. This regimen has prevented coagulation dysregulation, allowing spontaneous platelet count recovery, and-for the first time-has achieved 25-and 29-day survival, making clinical applicability as a bridge to allotransplantation a realistic consideration.
Relentless thrombocytopenia, porcine graft TMA, and consumptive coagulopathy have previously been hypothesized to be due to interspecies incompatibilities of cellsurface receptor-ligand interactions between pig endothelial cells and primate platelets (14, 15) or secondary to the presence of natural antibodies to porcine liver endothelial antigens, leading to endothelial cell activation, causing TMA (14, 15) . On the basis of these hypotheses, deletion of the presumed porcine carbohydrate xenoantigen targets through gene editing has been advocated as the only means of overcoming these barriers to even short-term survival following LXT (1, (15) (16) (17) (18) . Indeed, it had been suggested subsequently that in the absence of further genetic modifications, the incompatibilities limiting LXT are insurmountable (19) . Our data work toward refuting this hypothesis, especially in the setting of using a liver xenograft for bridging therapy, by demonstrating that it is possible to achieve survival of almost 1 mo using currently available GalT-KO miniature swine donors. Future investigation is needed to ascertain not only the specific coagulation factors responsible for the prevention of lethal coagulopathy but also the length of time postoperatively that exogenous factors are required. The acute portal vein thrombosis that developed late in the course of baboon 4 raises the possibility that the need for exogenous coagulation factor infusion is probably transient rather than lifelong, as the balance shifted to a procoagulant state in the setting of a normally functioning liver xenograft, supplemented with exogenous hPCC, and accentuated by the degree of postsplenectomy thrombocytosis observed. The resolution of thrombocytopenia that we observed indicates that this previously severe complication-thought to require genetic modification of the donor pigs to overcome-is actually transient with currently available GalT-KO donors when exogenous coagulation factors are provided in the postoperative period. Further investigations of the interplay among exogenous human coagulation factor administration, spontaneous platelet count recovery with eventual postsplenectomy thrombocytosis, and the avoidance of TMA are clearly warranted and are in progress.
The elimination of pCMV in donor organs may have played a critical role in prolonging survival. Mueller et al in 2002 described the upregulation of pCMV in five of six kidney xenograft recipients, leading to accelerated graft loss (20) . Infection by CMV was native tissue specific, that is, pCMV was limited to the xenograft without detectable dissemination despite intensive immunosuppression regimens. It was subsequently shown that pCMV induces endothelial activation in vitro with subsequent procoagulant expression (i.e. increased levels of porcine tissue factor [21] ) and that utilization of pCMV negative heart xenografts resulted in avoidance of consumptive coagulopathy in baboon recipients (22) . Yamada et al demonstrated the correlation of pCMV positivity of donors and markedly shortened survival of pig-to-primate renal transplants (from 48 to 14 days) in their model (7) . In a parallel study, transplantation of pCMV-positive versus -negative kidneys into cynomolgous monkeys shortened survival from an average of 28.7 to 9.2 days (23).
The accelerated graft loss occurred as a result of early rejection, accompanied by disseminated vascular coagulation and thrombocytopenia, similar to what was observed in our only recipient of a pCMV-positive xenoliver (baboon 3). Their conclusion was supported by results obtained using cesarean-derived, pCMV-negative donor kidneys from presumably pCMV-positive sows but hand reared and raised in isolation (7) . In this setting, kidney xenograft survival improved to an average of 53 days, comparable to results prior to introduction of pCMV into the source colony. Within our hPCC and costimulation blockade protocol, the sole recipient of a pCMV-positive liver xenograft succumbed to extensive hemorrhagic necrosis from antibody-mediated liver xenograft rejection on POD 8 and CMV infection. Because the ability and effort required to achieve pCMV-negative donors is not insignificant, further investigation into the role of donor pCMV status on LXT survival is warranted, with specific attention to its potential to influence antibody-mediated rejection following LXT.
We first reported the addition of costimulation blockade to our protocol in 2016, in which a belatacept-based regimen allowed for survival to improve from 9 to 25 days (5). This change came as a result of the encouraging results demonstrated by the addition of costimulation blockade in both renal and cardiac xenotransplantation models (24, 25) . More recently, Mohiuddin et al presented their results of an intensely dosed anti-CD40 mAb (2C10R4)-based regimen following cardiac xenotransplantation in transgenic GalT-KO with ATG and CD20 mAb-based induction (26) . The addition of anti-CD40 allowed for remarkable prolongation of survival to 945 days (previously 500 days) and, more important, allowed for consistent prevention of humoral rejection and coagulopathy. Furthermore, the benefits of anti-CD40 blockade in efficiently suppressing both cellular and humoral alloimmune responses have been demonstrated in a nonhuman primate model of hepatic allotransplantation (27) . Given these results and the detection of circulating cytotoxic IgM in two of our three belatacept-treated animals, pig-to-baboon LXT was subsequently performed with anti-CD40 mAb, which allowed for our longest survival to date (29 days) and without the development of baboon antipig cytotoxic antibodies. Because it appears that the addition of costimulation blockade may be critical in prolonging xenograft survival, not only in renal and cardiac models but also in the liver model, further assessment of the benefit of anti-CD40 mAb is warranted, given the potential to inhibit production of non-Gal baboon antipig cytotoxic antibodies.
Conclusion
We developed a novel approach comprised of (1) exogenous coagulation factor administration following pig-to-baboon LXT, which allowed for a reduction in postoperative blood transfusion requirements, spontaneous recovery of circulating platelets, and prevention of TMA; (2) addition of costimulation blockade to our previous immunosuppression regimen; and (3) use of pCMV-free donors. Using this approach, we achieved one 25-day (5) and now one 29-day rejection-free survival. These results represent the longest worldwide survival recorded to date and represent an advance toward realistic consideration of the clinical applicability of LXT as a bridge to allotransplantation for patients with acute liver failure.
